Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study.

Dermatol Ther (Heidelb) · 2026 · PMC13237329 · PMID 42029886

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Pruritus and scaling also significantly improved by week 16 (all p < 0.001), with further minor reductions by week 52 for scaling, which did not reach statistical significance compared with week 16.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.